Main Services / Platforms
Antibody drugs lead to serious side effects because they cannot distinguish disease tissue from normal tissue. Universal Antibody Lock allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. ▪ Features: • Medication safety with minimized adverse effects • Elevating treatment efficacy for cancer cure • Precision-designed for targeting various cancers ▪ Partnering: PrecisemAb licenses Lock-antibodies for further clinical trials through: • Co-development of Lock-antibodies [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β • Customized Antibody Lock Design Service Including 4 steps to design your own Lock-antibody.
Business Interests
▪ Cooperation Partners of Lead Product-PSM101 ▪ Strategic Partners of ADC. ▪ Customized Antibody Lock design service ▪ Out-licensing of Lock-antibodies
Contact Info
Yun-Chi Lu
President & Co-Founder
+886-7-311-1577
yunchi.lu@precisemab.com